At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Not Yet Opened 03-18 16:00:00 EDT
1.49
-0.01
-0.67%
盘后1.46
-0.03-2.01%
19:38 EDT
High1.51Low1.45Vol813.73K
Open1.50D1 Closing1.50Amplitude4.00%
Mkt Cap87.40MTradable Cap42.23MTotal Shares58.66M
T/O1.20MT/O Rate2.87%Tradable Shares28.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology Completes $30 Million Public Stock Offering
TIPRANKS  ·  03-05
MAIA Biotechnology Completes $30 Million Public Stock Offering
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Reuters  ·  03-05
BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing
THOMSON REUTERS  ·  03-05
Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing
Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing
THOMSON REUTERS  ·  03-05
Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire  ·  03-05
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
BUZZ-MAIA Biotechnology plunges after $30 million share sale
Reuters  ·  03-03
BUZZ-MAIA Biotechnology plunges after $30 million share sale
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
TIPRANKS  ·  03-03
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
MAIA Biotechnology announces common stock offering, no amount given
TIPRANKS  ·  03-03
MAIA Biotechnology announces common stock offering, no amount given
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  03-03
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-02
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
MAIA Biotechnology published a 2026 Letter to Shareholders
TIPRANKS  ·  02-24
MAIA Biotechnology published a 2026 Letter to Shareholders
Maia Biotechnology Publishes February 2026 Shareholder Letter
Reuters  ·  02-24
Maia Biotechnology Publishes February 2026 Shareholder Letter
Maia Biotechnology Announces Availability of 2026 Shareholder Letter
Reuters  ·  02-24
Maia Biotechnology Announces Availability of 2026 Shareholder Letter
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
GlobeNewswire  ·  02-24
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
MAIA Biotechnology outlines 2026 goals for ateganosine program
TIPRANKS  ·  01-21
MAIA Biotechnology outlines 2026 goals for ateganosine program
MAIA Biotechnology highlights milestones, catalysts for FY26
TIPRANKS  ·  01-20
MAIA Biotechnology highlights milestones, catalysts for FY26
Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine
Reuters  ·  01-20
Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine
MAIA Biotechnology Highlights Strategy in New Investor Presentation
TIPRANKS  ·  01-14
MAIA Biotechnology Highlights Strategy in New Investor Presentation
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  01-12
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
GlobeNewswire  ·  2025-12-24
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--